18 Feb
2022
15:22 E.S.T.

Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Read more

10 Feb
2022
16:44 E.S.T.

Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

Read more

10 Jan
2022
16:30 E.S.T.

Cellectis’ Licensed Partner, Allogene Therapeutics,  Announces Removal of FDA Clinical Hold on their Clinical Trials

Read more

04 Jan
2022
14:37 E.S.T.

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

Read more

11 Dec
2021
10:11 E.S.T.

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Read more

18 Nov
2021
13:44 E.S.T.

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Read more

11 Nov
2021
17:19 E.S.T.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Read more

04 Nov
2021
14:51 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

Read more

03 Nov
2021
18:40 E.S.T.

Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01

Read more

28 Oct
2021
11:08 E.S.T.

Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT

Read more